The National Cancer Institute and Cannabis and Cannabinoids Research. Issue 58 (27th November 2021)

• Record Type: Journal Article
• Authors: Ellison, Gary L; Alejandro Salicrup, L; Freedman, Andrew N; Fu, Yali; Ross, Sharon; Johnson, Ronald L; Bakos, Alexis; White, Jeffrey D
• Is Part Of: Journal of the National Cancer Institute. Volume 2021:Issue 58(2021)
• Page Start: 35
• Page End: 38
• Publication Date: 2021-11-27
• Subjects: Cancer -- Periodicals; Cancer -- Congresses; 616.994
• DOI: 10.1093/jncimonographs/lgab014
• Languages: English
• ISSNs: 1052-6773

Abstract

Abstract: The landscape of both recreational and medicinal cannabis use has changed dramatically over the past decade; however, research examining the risks and benefits of cannabis and cannabinoid use has lagged significantly behind the increased media promotion and their use by the general public and cancer patients. The National Cancer Institute (NCI) has supported cannabis-related research projects and funding opportunity announcements. In addition, NCI organized a virtual symposium on December 15-18, 2020, to discuss recent research findings on the use of cannabis and cannabinoids in relationship to cancer risk, prevention, and care. Specifically, the symposium sought to highlight the state of the science regarding cannabis, including the chemical constituents of cannabis (eg, cannabinoids), and cancer research involving cannabis, including cancer epidemiology, use in cancer patients, cancer biology and prevention, and preclinical and clinical cancer symptom and treatment side effect management with cannabis and cannabinoids as therapeutics. The symposium identified promising areas of future study, current barriers to conducting the research, and strategies to overcome those barriers. The series of papers in this special edition provide a summary of the symposium sessions as well as a synopsis of opportunities and challenges related to conducting research in this area.